Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Study Details
Study Description
Brief Summary
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is an open-label, non-randomized, four-cohort study, in which intravenous pembrolizumab will be combined with 4 different schedules of administration of CC-486 (oral azacitidine), for the treatment of platinum-resistant/refractory (EOC). This is also a futility trial for the strategy to combine pembrolizumab and CC-486 in EOC. Eligible subjects will be treated in one of four cohorts of combined oral CC-486 and intravenous pembrolizumab (200 mg intravenous (IV) every 3 weeks in all cohorts) to evaluate the safety of each combination schedule and to have preliminary data on their efficacy. The primary objective is to establish the optimal dosing schedule for comparison with pembrolizumab alone.
Subjects will be assigned to a treatment cohort in the order they are enrolled in the study. In all subjects, tumor tissue will be obtained via image-guided core biopsy at study entry and 6 weeks after commencing treatment with CC-486. A cohort will remain open to accrual until five subjects treated on that cohort have completed two CC-486 cycles and have had the first post-baseline tumor burden assessment and both tumor biopsies performed and adequate paired tissue obtained. At least 5 evaluable subjects per cohort will be accrued over an estimated period of approximately 24 months.
Subjects will be treated in the assigned cohort until progressive disease based on Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST), unacceptable toxicity, consent withdrawal or the Investigator concludes that it is in the subject´s best interest to discontinue. Once 5 subjects in each cohort are considered evaluable for response, toxicity and treatment responses will be analyzed for each of the four cohorts and an optimal schedule will be selected.
This study includes mandatory tumor core biopsies for biomarkers research and mandatory whole blood sampling for deoxyribonucleic acid (DNA) methylation analyses.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Cohort 1 CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days |
Drug: CC-486
CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
Other Names:
Biological: Pembrolizumab
Pembrolizumab 200 mg IV every 21 days
Other Names:
|
| Active Comparator: Cohort 2 CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days |
Drug: CC-486
CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
Other Names:
Biological: Pembrolizumab
Pembrolizumab 200 mg IV every 21 days
Other Names:
|
| Active Comparator: Cohort 3 CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days |
Drug: CC-486
CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
Other Names:
Biological: Pembrolizumab
Pembrolizumab 200 mg IV every 21 days
Other Names:
|
| Active Comparator: Cohort 4 CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days |
Drug: CC-486
CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
Other Names:
Biological: Pembrolizumab
Pembrolizumab 200 mg IV every 21 days
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Subjects With Grade 3, 4, or 5 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [The average time period for patient participation was 30 weeks.]
Safety evaluation: number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency, severity and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings.
- Number of Subjects With Immune-related Partial Response (irPR), Immune-related Complete Response (irCR), Immune-related Stable Disease (irSD), Immune-related Progressive Disease (irPD), and Immune-related Not Evaluable (irNE) as Assessed by irRECIST. [The average time period for patient participation was 30 weeks.]
Efficacy evaluation: based on the Immune-related Objective Response Rate (irORR)/ Immune-related Disease Control Rate (irDCR) per Immune-Related Response Evaluation Criteria In Solid Tumor (irRECIST) criteria using the intent-to-treat (ITT) population (all patients who were enrolled in the study, regardless of whether they actually received study medication). The best overall response outcome (irCR/irPR/irSD/irPD/irNE) will be summarized and tabulated for ITT by cohort.
- Number of Subjects With Treatment Emergent Adverse Events Related to CC-486 as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03. [The average time period for patient participation was 30 weeks.]
Safety evaluation: number of subjects with treatment emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings.
- Number of Subjects With Treatment Emergent Adverse Events Related to Pembrolizumab as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03. [The average time period for patient participation was 30 weeks.]
Safety evaluation: number of subjects with treatment emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed and dated informed consent document obtained prior to initiation of any study-specific procedure and treatment (by the subject or a legally acceptable representative as per the local regulations).
-
Women ≥ 18 years old
-
Histologically confirmed Epitheilial Ovarian Cancer (EOC), Fallopian Tube Cancer (FTC) or Primary Peritoneal Cancer (PPC).
-
Received debulking surgery and preoperative and/or postoperative platinum-based frontline chemotherapy (intravenous and/or intraperitoneal) for the treatment of EOC/FTC/PPC.
-
Documented platinum-resistant or platinum-refractory disease. Platinum-resistant disease is defined as progression within < 6 months from completion of a minimum of 4 platinum frontline therapy cycles in the pre or postoperative setting (the date should be calculated from the last administered dose of platinum agent). Platinum-refractory is defined as disease that has recurred/progressed while receiving platinum-based frontline therapy.
-
Measurable disease according to Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)
-
Indication of systemic treatment for the relapsed EOC, FTC or PPC.
-
Subjects must have a tumor lesion that is amenable to an image-guided core biopsy and willingness to undergo two biopsies (baseline and 6 weeks after first dose of study treatment).
-
Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 or 1.
-
Expected survival of more than 6 months.
-
Adequate organ function within 7 days prior to enrollment, as defined by the following criteria:
-
Absolute neutrophils count (ANC) ≥ 1.5 x 10E9/L, platelets ≥ 100 x 10E9/L, hemoglobin > 9 g/dL (without transfusion or erythropoiesis stimulating agents' dependency).
-
Serum creatinine ≤ 1.5 x upper limit of normal (ULN).
-
Total serum bilirubin ≤ 1.5 x ULN regardless of liver involvement secondary to tumor. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
-
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) < 2.0 x ULN or ≤ 5 X ULN for subjects with liver metastases.
-
International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
-
Partial Thromboplastin Time (PTT) or Activated Partial Thromboplastin Time (aPTT) ≤ 40 seconds unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
-
For women of childbearing potential, negative serum pregnancy test within 7 days of enrollment
-
Women of childbearing potential must agree to use acceptable methods of birth control starting with the screening visit and up to 120 days after the last dose of study treatment. Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation.
-
Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
Exclusion Criteria:
-
Non-epithelial ovarian cancers, including malignant mixed Müllerian tumors.
-
Ovarian tumors with low malignant potential (i.e. borderline tumors).
-
Relapse/progression based solely on elevation of CA-125, in absence of measurable disease, according to irRECIST criteria.
-
More than 2 prior treatment regimens for the platinum-resistant/refractory relapsed EOC, FTC, or PTC, defined as investigational, chemotherapy, hormonal, biologic, or targeted therapy.
-
Any concurrent or previous malignancy within 5 years prior to enrollment except for adequately and radically treated basal or squamous skin cancer, or carcinoma in situ of the cervix, or other non-invasive/in-situ neoplasm. A subject with previous history of invasive malignancy (other than adequately and radically treated basal or squamous skin cancer or carcinomas in situ) is eligible provided that she has been disease free for more than 5 years.
-
Brain metastases (even if treated and/or stable), spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.
-
Prior systemic anticancer therapy within 4 weeks prior to enrollment or who has not recovered (i.e. ≤ Grade 1 or baseline grade) from adverse events due to a previously administered agent
-
Prior treatment with a monoclonal antibody within 4 weeks prior to enrollment or who has not recovered (i.e. ≤ Grade 1 or baseline grade) from adverse events due to agents administered more than 4 weeks earlier.
-
Diagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment . The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.
-
Active autoimmune disease or history of autoimmune disease or syndrome that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects with vitiligo or resolved childhood asthma/atopy will not be excluded.
-
Received live vaccines within 30 days prior to enrollment
-
Current or prior history of myelodysplastic syndrome, leukemia or clinically significant (as per Investigator judgment) bone marrow failure.
-
Uncontrolled systemic fungal, bacterial or viral infection at time of enrollment (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment).
-
Known history of active TB (Bacillus Tuberculosis).
-
Known HIV infection or known history of Hepatitis B or known positivity for active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative] is detected).
-
Known history of non-infectious pneumonitis that required steroids or has current pneumonitis (infectious or non-infectious).
-
Significant active cardiac disease within 6 months prior to enrollment, including but not limited to New York Heart Association class 4 cardiac heart failure, unstable angina, myocardial infarction
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. Is or has an immediate family member (e.g. spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
-
Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.
-
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
-
Prior treatment with any anti-Programmed Death (PD)-1, or PD-L1 or PD-L2 agent; or with azacitidine (any formulation) or any other hypomethylating agent; or with anti-cytoplasmic (CD) 137, or anti-cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 antibody (including ipilimumab) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
-
Known or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.
-
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to enrollment .
-
Pregnant or lactating women or is expecting to conceive children or breastfeed within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA | Los Angeles | California | United States | 90095 |
| 2 | Johns Hopkins University | Baltimore | Maryland | United States | 21287 |
| 3 | University of Minnesota | Minneapolis | Minnesota | United States | 55455 |
| 4 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Translational Research in Oncology
- Celgene
Investigators
- Study Director: Rodrigo Fresco, MD, Translational Research in Oncology
Study Documents (Full-Text)
More Information
Publications
None provided.- TRIO026
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days |
| Period Title: Overall Study | ||||
| STARTED | 9 | 10 | 7 | 8 |
| COMPLETED | 7 | 10 | 7 | 8 |
| NOT COMPLETED | 2 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Total |
|---|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | Total of all reporting groups |
| Overall Participants | 9 | 10 | 7 | 8 | 34 |
| Age (years) [Mean (Standard Deviation) ] | |||||
| Mean (Standard Deviation) [years] |
58.0
(8.89)
|
59.9
(13.15)
|
63.7
(12.47)
|
68.0
(6.39)
|
62.2
(11.20)
|
| Sex: Female, Male (Count of Participants) | |||||
| Female |
9
100%
|
10
100%
|
7
100%
|
8
100%
|
34
100%
|
| Male |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
2
22.2%
|
0
0%
|
1
14.3%
|
0
0%
|
3
8.8%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| White |
7
77.8%
|
10
100%
|
6
85.7%
|
7
87.5%
|
30
88.2%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
1
12.5%
|
1
2.9%
|
| Primary Tumor Location (Count of Participants) | |||||
| Epithelial Ovarian Cancer |
7
77.8%
|
9
90%
|
6
85.7%
|
4
50%
|
26
76.5%
|
| Fallopian Tube Carcinoma |
1
11.1%
|
0
0%
|
1
14.3%
|
4
50%
|
6
17.6%
|
| Primary Peritoneal Carcinoma |
1
11.1%
|
1
10%
|
0
0%
|
0
0%
|
2
5.9%
|
Outcome Measures
| Title | Number of Subjects With Grade 3, 4, or 5 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 |
|---|---|
| Description | Safety evaluation: number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency, severity and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings. |
| Time Frame | The average time period for patient participation was 30 weeks. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is completed using the Safety Population as opposed to the "Intent-to-Treat" Population (all patients who were enrolled in the study, regardless of whether they actually received study medication). The Safety Population consists of all patients who receive any study treatment, and will be used for the analysis of safety data of the study. |
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days |
| Measure Participants | 7 | 10 | 7 | 8 |
| Patients with any Grade 3 or 4 Adverse Event |
5
55.6%
|
8
80%
|
5
71.4%
|
7
87.5%
|
| Patients with Grade 5 Adverse Event |
1
11.1%
|
0
0%
|
0
0%
|
0
0%
|
| Patients without Grade 3, 4, or 5 Adverse Event |
1
11.1%
|
2
20%
|
2
28.6%
|
1
12.5%
|
| Title | Number of Subjects With Immune-related Partial Response (irPR), Immune-related Complete Response (irCR), Immune-related Stable Disease (irSD), Immune-related Progressive Disease (irPD), and Immune-related Not Evaluable (irNE) as Assessed by irRECIST. |
|---|---|
| Description | Efficacy evaluation: based on the Immune-related Objective Response Rate (irORR)/ Immune-related Disease Control Rate (irDCR) per Immune-Related Response Evaluation Criteria In Solid Tumor (irRECIST) criteria using the intent-to-treat (ITT) population (all patients who were enrolled in the study, regardless of whether they actually received study medication). The best overall response outcome (irCR/irPR/irSD/irPD/irNE) will be summarized and tabulated for ITT by cohort. |
| Time Frame | The average time period for patient participation was 30 weeks. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis was performed on the intent-to-treat (ITT) population (i.e., patients who were enrolled in the study, regardless of whether they actually received study medication), which is different from the safety population (i.e., patients who receive any study treatment) used for safety analysis. |
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days |
| Measure Participants | 9 | 10 | 7 | 8 |
| irPR |
0
0%
|
0
0%
|
1
14.3%
|
0
0%
|
| irCR |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| irSD |
3
33.3%
|
6
60%
|
3
42.9%
|
4
50%
|
| irPD |
5
55.6%
|
2
20%
|
1
14.3%
|
4
50%
|
| irNE |
0
0%
|
1
10%
|
0
0%
|
0
0%
|
| Missing |
1
11.1%
|
1
10%
|
2
28.6%
|
0
0%
|
| Title | Number of Subjects With Treatment Emergent Adverse Events Related to CC-486 as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03. |
|---|---|
| Description | Safety evaluation: number of subjects with treatment emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings. |
| Time Frame | The average time period for patient participation was 30 weeks. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is completed using the Safety Population as opposed to the "Intent-to-Treat" Population (all patients who were enrolled in the study, regardless of whether they actually received study medication). The Safety Population consists of all patients who receive any study treatment, and will be used for the analysis of safety data of the study. |
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days |
| Measure Participants | 7 | 10 | 7 | 8 |
| Count of Participants [Participants] |
7
77.8%
|
10
100%
|
7
100%
|
8
100%
|
| Title | Number of Subjects With Treatment Emergent Adverse Events Related to Pembrolizumab as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03. |
|---|---|
| Description | Safety evaluation: number of subjects with treatment emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This is an assessment of the frequency and relationship to trial treatment of all adverse events that occurred while on trial. CTCAE is a standard classification and severity grading scale (from 1- mild to 5 - death) for adverse events in clinical trials and oncology settings. |
| Time Frame | The average time period for patient participation was 30 weeks. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is completed using the Safety Population as opposed to the "Intent-to-Treat" Population (all patients who were enrolled in the study, regardless of whether they actually received study medication). The Safety Population consists of all patients who receive any study treatment, and will be used for the analysis of safety data of the study. |
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days |
| Measure Participants | 7 | 10 | 7 | 8 |
| Count of Participants [Participants] |
6
66.7%
|
5
50%
|
6
85.7%
|
3
37.5%
|
Adverse Events
| Time Frame | Adverse Event data were collected the from the time when the first patient consented (signed informed consent form) to the end of study for the last patient. The average timeframe for patient participation was 30 weeks for which data was collected/assessed. | |||||||
|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | The SAFETY population was used to assess clinical safety and tolerability and consisted of all subjects who were enrolled (Part A) and received at least one dose of study medication (this is different from the intent-to-treat population, which included all patients enrolled in the study, irrespective of treatment). All adverse experiences observed by the Investigator or reported by the patient were collected at each visit and any contact during the study and follow-up period. | |||||||
| Arm/Group Title | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | ||||
| Arm/Group Description | CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days CC-486: CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet Pembrolizumab: Pembrolizumab 200 mg IV every 21 days | ||||
All Cause Mortality |
||||||||
| Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/7 (85.7%) | 4/10 (40%) | 1/7 (14.3%) | 3/8 (37.5%) | ||||
Serious Adverse Events |
||||||||
| Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/7 (42.9%) | 6/10 (60%) | 3/7 (42.9%) | 1/8 (12.5%) | ||||
| Blood and lymphatic system disorders | ||||||||
| Neutropenia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Febrile neutropenia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Cardiac disorders | ||||||||
| Cardiac arrest | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Pericardial effusion | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Gastrointestinal disorders | ||||||||
| Small intestinal obstruction | 0/7 (0%) | 2/10 (20%) | 0/7 (0%) | 0/8 (0%) | ||||
| Abdominal pain | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Ascites | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Melaena | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Stomatitis | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| General disorders | ||||||||
| Fatigue | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Infections and infestations | ||||||||
| Bacteraemia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Pneumonia | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Sepsis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Investigations | ||||||||
| White blood cell count decreased | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Neutrophil count decreased | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||
| Malignant pleural effusion | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Nervous system disorders | ||||||||
| Cerebral infarction | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Cerebrovascular accident | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Dyspnoea | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Pulmonary embolism | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Skin and subcutaneous tissue disorders | ||||||||
| Urticaria | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Vascular disorders | ||||||||
| Embolism | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Hypotension | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Thrombosis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
Other (Not Including Serious) Adverse Events |
||||||||
| Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 7/7 (100%) | 10/10 (100%) | 7/7 (100%) | 8/8 (100%) | ||||
| Blood and lymphatic system disorders | ||||||||
| Anaemia | 3/7 (42.9%) | 3/10 (30%) | 3/7 (42.9%) | 4/8 (50%) | ||||
| Neutropenia | 0/7 (0%) | 2/10 (20%) | 4/7 (57.1%) | 3/8 (37.5%) | ||||
| Lymphopenia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 3/8 (37.5%) | ||||
| Thrombocytosis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Febrile neutropenia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Cardiac disorders | ||||||||
| Palpitations | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Cardiac arrest | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Pericardial effusion | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Tachycardia | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Ear and labyrinth disorders | ||||||||
| External ear pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Vertigo | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Endocrine disorders | ||||||||
| Hypothyroidism | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Hyperthyroidism | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Eye disorders | ||||||||
| Vision blurred | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Visual impairment | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Vitreous floaters | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Gastrointestinal disorders | ||||||||
| Vomiting | 5/7 (71.4%) | 6/10 (60%) | 7/7 (100%) | 8/8 (100%) | ||||
| Nausea | 5/7 (71.4%) | 7/10 (70%) | 5/7 (71.4%) | 7/8 (87.5%) | ||||
| Constipation | 7/7 (100%) | 4/10 (40%) | 5/7 (71.4%) | 3/8 (37.5%) | ||||
| Diarrhoea | 3/7 (42.9%) | 4/10 (40%) | 4/7 (57.1%) | 7/8 (87.5%) | ||||
| Abdominal Pain | 2/7 (28.6%) | 3/10 (30%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Ascites | 3/7 (42.9%) | 1/10 (10%) | 0/7 (0%) | 2/8 (25%) | ||||
| Abdominal Distension | 1/7 (14.3%) | 2/10 (20%) | 0/7 (0%) | 2/8 (25%) | ||||
| Gastrooesophageal Reflux Disease | 2/7 (28.6%) | 0/10 (0%) | 0/7 (0%) | 2/8 (25%) | ||||
| Dyspepsia | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Stomatitis | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Abdominal Pain Lower | 1/7 (14.3%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Dry mouth | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Flatulence | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Impaired Gastric Emptying | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Retching | 0/7 (0%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Small Intestinal Obstruction | 0/7 (0%) | 2/10 (20%) | 0/7 (0%) | 0/8 (0%) | ||||
| Abdominal Pain Upper | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Epigastric Discomfort | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Intestinal Obstruction | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Melaena | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| General disorders | ||||||||
| Fatigue | 5/7 (71.4%) | 3/10 (30%) | 6/7 (85.7%) | 7/8 (87.5%) | ||||
| Pyrexia | 4/7 (57.1%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Odema Peripheral | 1/7 (14.3%) | 1/10 (10%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Chills | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Influenza like illness | 0/7 (0%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Asthenia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Catheter site pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Early satiety | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Non-cardiac chest pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Oedema | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Pain | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Infections and infestations | ||||||||
| Pneumonia | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 2/8 (25%) | ||||
| Urinary tract infection | 0/7 (0%) | 1/10 (10%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Bacteraemia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Bronchitis | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Diverticulitis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Fungal infection | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Labyrinthitis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Nasopharyngitis | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Sepsis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Systemic candida | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Injury, poisoning and procedural complications | ||||||||
| Arthropod bite | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Arthropod sting | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Contusion | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Fall | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Investigations | ||||||||
| Aspartate aminotransferase increased | 4/7 (57.1%) | 1/10 (10%) | 0/7 (0%) | 3/8 (37.5%) | ||||
| White blood cell count decreased | 0/7 (0%) | 1/10 (10%) | 2/7 (28.6%) | 5/8 (62.5%) | ||||
| Blood alkaline phosphatase increased | 4/7 (57.1%) | 1/10 (10%) | 0/7 (0%) | 2/8 (25%) | ||||
| Lymphocyte count decreased | 1/7 (14.3%) | 2/10 (20%) | 2/7 (28.6%) | 2/8 (25%) | ||||
| Weight decreased | 2/7 (28.6%) | 1/10 (10%) | 1/7 (14.3%) | 3/8 (37.5%) | ||||
| Alanine aminotransferase increased | 3/7 (42.9%) | 1/10 (10%) | 0/7 (0%) | 2/8 (25%) | ||||
| Neutrophil count decreased | 0/7 (0%) | 1/10 (10%) | 1/7 (14.3%) | 3/8 (37.5%) | ||||
| Platelet count decreased | 1/7 (14.3%) | 2/10 (20%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Blood creatinine increased | 0/7 (0%) | 0/10 (0%) | 2/7 (28.6%) | 1/8 (12.5%) | ||||
| Blood bilirubin increased | 0/7 (0%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Blood creatinine decreased | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Breath sounds abnormal | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Glomerular filtration rate decreased | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Neutrophil count increased | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Platelet count increased | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Protein total decreased | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Weight increased | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Metabolism and nutrition disorders | ||||||||
| Decreased Appetite | 3/7 (42.9%) | 6/10 (60%) | 4/7 (57.1%) | 6/8 (75%) | ||||
| Hyperglycaemia | 3/7 (42.9%) | 1/10 (10%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Dehydration | 2/7 (28.6%) | 0/10 (0%) | 1/7 (14.3%) | 2/8 (25%) | ||||
| Hypoalbuminaemia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 2/8 (25%) | ||||
| Hypokalaemia | 2/7 (28.6%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Hyponatraemia | 2/7 (28.6%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Hypocalcaemia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Hypomagnesaemia | 2/7 (28.6%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Hypercalcaemia | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Hyperkalaemia | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Hypovolaemia | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Increased appetite | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Malnutrition | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Metabolic acidosis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Musculoskeletal and connective tissue disorders | ||||||||
| Back pain | 2/7 (28.6%) | 2/10 (20%) | 0/7 (0%) | 2/8 (25%) | ||||
| Myalgia | 1/7 (14.3%) | 1/10 (10%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Arthralgia | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Flank pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 2/8 (25%) | ||||
| Groin pain | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Musculoskeletal chest pain | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Joint swelling | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Muscle spasms | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Musculoskeletal pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Neck pain | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Pain in extremity | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Rotator cuff syndrome | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||
| Malignant pleural effusion | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Nervous system disorders | ||||||||
| Headache | 5/7 (71.4%) | 1/10 (10%) | 6/7 (85.7%) | 4/8 (50%) | ||||
| Neuropathy peripheral | 2/7 (28.6%) | 0/10 (0%) | 1/7 (14.3%) | 2/8 (25%) | ||||
| Dizziness | 0/7 (0%) | 0/10 (0%) | 3/7 (42.9%) | 1/8 (12.5%) | ||||
| Peripheral sensory neuropathy | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Balance disorder | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Cerebral infarction | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Cerebrovascular accident | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Dysgeusia | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Loss of consciousness | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Memory impairment | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Neuralgia | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Somnolence | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Syncope | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Taste disorder | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Psychiatric disorders | ||||||||
| Insomnia | 3/7 (42.9%) | 2/10 (20%) | 0/7 (0%) | 2/8 (25%) | ||||
| Anxiety | 1/7 (14.3%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Depressed mood | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Depression | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Libido decreased | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Renal and urinary disorders | ||||||||
| Acute kidney injury | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Dysuria | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Urinary incontinence | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Reproductive system and breast disorders | ||||||||
| Vaginal discharge | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Vaginal haemorrhage | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Dyspnoea | 5/7 (71.4%) | 3/10 (30%) | 3/7 (42.9%) | 2/8 (25%) | ||||
| Pleural Effusion | 4/7 (57.1%) | 1/10 (10%) | 2/7 (28.6%) | 1/8 (12.5%) | ||||
| Cough | 2/7 (28.6%) | 2/10 (20%) | 2/7 (28.6%) | 1/8 (12.5%) | ||||
| Pulmonary Embolism | 1/7 (14.3%) | 3/10 (30%) | 0/7 (0%) | 0/8 (0%) | ||||
| Oropharyngeal pain | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 2/8 (25%) | ||||
| Atelectasis | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Epistaxis | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Nasal congestion | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Pneumothorax | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Productive cough | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Tachypnoea | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Throat irritation | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Skin and subcutaneous tissue disorders | ||||||||
| Rash maculo-papular | 1/7 (14.3%) | 1/10 (10%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Alopecia | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 2/8 (25%) | ||||
| Dry skin | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Pruritus | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Rash | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Urticaria | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 1/8 (12.5%) | ||||
| Hair growth abnormal | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Night sweats | 0/7 (0%) | 0/10 (0%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Rash macular | 0/7 (0%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Vascular disorders | ||||||||
| Hot flush | 1/7 (14.3%) | 1/10 (10%) | 0/7 (0%) | 1/8 (12.5%) | ||||
| Embolism | 1/7 (14.3%) | 0/10 (0%) | 1/7 (14.3%) | 0/8 (0%) | ||||
| Deep vein thrombosis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
| Hypotension | 0/7 (0%) | 1/10 (10%) | 0/7 (0%) | 0/8 (0%) | ||||
| Thrombosis | 1/7 (14.3%) | 0/10 (0%) | 0/7 (0%) | 0/8 (0%) | ||||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
No publication, abstract or presentation of the study will be made without the approval of the Study Steering Committee (SSC).
Results Point of Contact
| Name/Title | Director, Project Management |
|---|---|
| Organization | Translational Research In Oncology (TRIO) |
| Phone | 33 158 10 09 09 |
| 026@trioncology.org |
- TRIO026